Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AVTX Avalo Therapeutics Inc

Pre-Mkt 04-30 05:11:16 EDT

13.20

+0.34

+2.64%

盘前13.40

+0.20+1.52%

04:12 EDT

High13.53	Low12.51	Vol768.24K
Open12.86	D1 Closing12.86	Amplitude7.89%
Mkt Cap352.63M	Tradable Cap279.74M	Total Shares26.71M
T/O10.08M	T/O Rate3.63%	Tradable Shares21.19M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AVTX","market":"US","secType":"STK","nameCN":"Avalo Therapeutics Inc","latestPrice":13.2,"timestamp":1777492800000,"preClose":12.86,"halted":0,"volume":768236,"hourTrading":{"tag":"盘前","latestPrice":13.4,"preClose":13.2,"latestTime":"04:12 EDT","volume":2,"amount":26.7,"timestamp":1777536779735,"change":0.2,"changeRate":0.015152,"amplitude":0.007576},"delay":0,"changeRate":0.026438569206842913,"floatShares":21192700,"shares":26714337,"eps":-5.839999,"marketStatus":"Pre-Mkt","change":0.34,"latestTime":"04-30 05:11:16 EDT","open":12.86,"high":13.525,"low":12.51,"amount":10076115.002996,"amplitude":0.078927,"askPrice":15.18,"askSize":100,"bidPrice":10.43,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.839999,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777555800000},"marketStatusCode":1,"adr":0,"listingDate":1447390800000,"exchange":"NASDAQ","adjPreClose":13.2,"preHourTrading":{"tag":"盘前","latestPrice":13.4,"preClose":13.2,"latestTime":"04:12 EDT","volume":2,"amount":26.7,"timestamp":1777536779735,"change":0.2,"changeRate":0.015152,"amplitude":0.007576},"postHourTrading":{"tag":"盘后","latestPrice":13.89,"preClose":13.2,"latestTime":"19:42 EDT","volume":16531,"amount":218918.9544,"timestamp":1777506146996,"change":0.69,"changeRate":0.052273,"amplitude":0.055985},"volumeRatio":1.0907822848230357,"optionData":{"bulkOrders":[{"symbol":"AVTX","call":true,"expireDate":1778817600000,"strike":"30.0","timestamp":1777482647157,"price":2.2,"volume":2500,"amount":550000,"type":"+"}]},"impliedVol":3.8209,"impliedVolPercentile":0.94},"requestUrl":"/m/hq/s/AVTX/wiki","defaultTab":"wiki","newsList":[{"id":"2630305511","title":"BRIEF-Avalo Therapeutics Enters Milestone Buyout Option Agreement On April 26 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630305511","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630305511?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:13","pubTimestamp":1777374800,"startTime":"0","endTime":"0","summary":"BRIEF-Avalo Therapeutics Enters Milestone Buyout Option Agreement On April 26 - SEC FilingApril 28  - SEC Filing:AVALO THERAPEUTICS INC - ENTERS MILESTONE BUYOUT OPTION AGREEMENT ON APRIL 26, 2026 - SEC FILINGAVALO THERAPEUTICS INC - TO PAY $2.25 MILLION TO SECURITYHOLDERS' REPRESENTATIVE WITHIN FIVE BUSINESS DAYS OF APRIL 26, 2026 - SEC FILINGSource text: [ID:n0001534120-26-000026]Further company coverage: AVTX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0P1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630305322","title":"Avalo Therapeutics Inc - Avalo Has Agreed to Pay $2.25 Mln to Former Almatabio Securityholders for an Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2630305322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630305322?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:12","pubTimestamp":1777374722,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0P2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630779303","title":"Avalo Therapeutics Inc - to Pay $2.25 Mln to Securityholders' Representative Within Five Business Days of April 26, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630779303","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630779303?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:08","pubTimestamp":1777374511,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0P1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630303727","title":"Avalo Therapeutics Inc - Enters Milestone Buyout Option Agreement on April 26, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630303727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630303727?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:08","pubTimestamp":1777374511,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nFWN41B0P1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630303017","title":"Avalo buys option to cut AlmataBio milestone payment to $5.13 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2630303017","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630303017?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:08","pubTimestamp":1777374505,"startTime":"0","endTime":"0","summary":"Avalo entered a milestone buyout option agreement tied to its March 2024 acquisition of AlmataBio.Deal sets a USD 2.25 million payment to former AlmataBio securityholders for an option exercisable within 90 days.Option would allow an additional USD 5.125 million payment in cash or Avalo common stock, or a mix, in place of a previously disclosed USD 15 million contingent milestone.Replaced milestone had been payable when first patient is dosed in a Phase 3 trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on April 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL1WgvQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630303047","title":"Press Release: Avalo Therapeutics Purchases Optional Milestone Buyout","url":"https://stock-news.laohu8.com/highlight/detail?id=2630303047","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630303047?lang=en_us&edition=fundamental","pubTime":"2026-04-28 19:00","pubTimestamp":1777374000,"startTime":"0","endTime":"0","summary":"WAYNE, Pa., April 28, 2026  -- Avalo Therapeutics, Inc.  , a clinical-stage biotechnology company fully dedicated to developing IL-1<BETA> based treatments for immune-mediated inflammatory diseases, today announced that it has entered into a Milestone Buyout Option and Amendment Agreement  related to the company's prior acquisition of AlmataBio, Inc. in March of 2024.Pursuant to the Buyout Agreement, Avalo has agreed to pay $2.25 million to the former AlmataBio securityholders for an option, exercisable within 90 days of the effective date, to pay an additional $5.125 million in cash or shares of Avalo common stock, or a combination thereof in lieu of a previously disclosed $15 million contingent milestone payment due upon the first patient being dosed in a Phase 3 trial.Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1<BETA>-based treatments for immune-mediated inflammatory diseases. Our lead asset, abdakibart , is in a Phase 2 clinical tr","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626411043","title":"Avalo Therapeutics announces annual shareholder meeting via virtual webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2626411043","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626411043?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:02","pubTimestamp":1775851365,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics schedules virtual annual shareholder meeting for June 2, 2026.Shareholders set to vote on election of seven directors for terms running to 2027 annual meeting.Ballot includes approval of second amended and restated 2016 employee stock purchase plan.Meeting agenda also includes ratification of Ernst & Young as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL38ZmqQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626933927","title":"Avalo CMO Doyle Mittie disposes 3,970 shares worth $71,511","url":"https://stock-news.laohu8.com/highlight/detail?id=2626933927","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626933927?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:52","pubTimestamp":1775681562,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 3,970 common shares on April 6, 2026 at USD 18.01 per share.Transaction followed exercise of stock options for 3,970 shares at USD 12.65 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLrz7fN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo CMO Doyle Mittie disposes 3,970 shares worth $71,511","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624615266","title":"Avalo CFO Christopher Sullivan disposes AVTX shares worth $0.3 million under 10b5-1 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624615266","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624615266?lang=en_us&edition=fundamental","pubTime":"2026-04-04 03:15","pubTimestamp":1775243729,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics CFO Christopher Ryan Sullivan sold 15,959 common shares on April 1-2.Sales were priced at about $15.86-$17.57 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL7JhpL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo CFO Christopher Sullivan disposes AVTX shares worth $0.3 million under 10b5-1 plan","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624615306","title":"Avalo CMO Mittie Doyle disposes Avalo Therapeutics common shares worth $0.01 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624615306","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624615306?lang=en_us&edition=fundamental","pubTime":"2026-04-04 03:14","pubTimestamp":1775243644,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 679 shares on April 1 at USD 16.Holdings in common stock fell to 3,622 shares following transactions.Mittie exercised options for 679 shares on April 1 at USD 8.04.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL8KlBHp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Avalo CMO Mittie Doyle disposes Avalo Therapeutics common shares worth $0.01 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622410870","title":"Avalo Therapeutics board changes; Goldman and Chan decline to seek re-election at FY2026 annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2622410870","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622410870?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:02","pubTimestamp":1774641738,"startTime":"0","endTime":"0","summary":"Jonathan Goldman and Mitchell Chan notified Avalo Therapeutics that they will not stand for re-election to the board at the 2026 annual stockholders meeting.Both directors are expected to continue serving on the board until the 2026 annual stockholders meeting.The company said their decisions were not related to any disagreement over operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL51kQp4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622022893","title":"Avalo Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $40 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2622022893","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622022893?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:17","pubTimestamp":1774433825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nAZN4SN51U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622023931","title":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2622023931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622023931?lang=en_us&edition=fundamental","pubTime":"2026-03-25 16:01","pubTimestamp":1774425680,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador ResourcesMarch 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Wedn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D0JI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVI","BZAI","BRZE","CVX","AVTX","CALM","ADUS","FIGG","BWXT","AZYY","AIR","ACAD","INSM","BXP","CEG","EVGO","HAL","USAW.SI","ARE","AVAH","CDE","BP","GLW","CNM","DINO","AMZU","BCAX","APEI","FIG","CEGX","HD","KBH","FANG","ESE","ABSI","MTDR","DK","AMZD","BTM","AMZP","FRPT","AFG","AARD","BAM","BPH","GENB","ELVN","DG","AMZN"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621709907","title":"Avalo Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2621709907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621709907?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:31","pubTimestamp":1774272675,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryAvalo Therapeutics Inc AVTX.OQ reported a quarterly adjusted loss of $1.13 per share for the quarter ended De","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B1D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770700","title":"Avalo Therapeutics Publishes Corporate Presentation on Abdakibart IL-1β Therapy for Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770700","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770700?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:34","pubTimestamp":1774265656,"startTime":"0","endTime":"0","summary":"Avalo outlined its focus on developing IL-1β therapies for immune-mediated inflammatory diseases, with abdakibart  as its lead anti-IL-1β monoclonal antibody.The company said enrollment is complete in the Phase 2 LOTUS trial in hidradenitis suppurativa, with topline data expected in Q2 2026.LOTUS is designed to evaluate two dosing regimens—600 mg then 300 mg subcutaneous every 4 weeks, and 300 mg then 150 mg subcutaneous every 2 weeks—versus placebo in about 250 participants.The primary endpoint is the percentage of participants achieving HiSCR75 at 16 weeks.Avalo said it expects its cash runway to extend into 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLb6KSJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770876","title":"Avalo Therapeutics posts lower-than-expected 2025 net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770876","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770876?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:12","pubTimestamp":1774264365,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics posts lower-than-expected 2025 net lossOverviewU.S. IL-1β drug developer's 2025 net loss is lower than expectedOperating expenses rose due to increased R&D for Phase 2 LOTUS trialOu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL1N40B0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777400","title":"Avalo Therapeutics FY2025 net loss widens 123% to USD 78 million, R&D expenses rise 105% to USD 50 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777400","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777400?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:01","pubTimestamp":1774263696,"startTime":"0","endTime":"0","summary":"Avalo published a full-year earnings release reporting a net loss of USD 78.3 million and a loss from operations of USD 72.9 million.Revenue was USD 59,000 and interest income, net was USD 4.4 million.Research and development expenses rose more than doubled to USD 50.1 million, driven by costs supporting the Phase 2 LOTUS trial.General and administrative expenses increased 33.1% to USD 22.9 million, primarily driven by stock-based compensation expense and headcount additions.Cash, cash equivalents and short-term investments were USD 98.3 million, and Avalo said it expects this to fund operations into 2028; management also said topline data from the Phase 2 LOTUS trial of abdakibart  in hidradenitis suppurativa are expected in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLbHq2SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621779347","title":"Avalo Therapeutics FY Operating Expenses USD 72.984 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621779347?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nPLXBFB307:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777265","title":"Press Release: Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777265","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777265?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:00","pubTimestamp":1774263600,"startTime":"0","endTime":"0","summary":"-- Topline data expected from Phase 2 LOTUS trial of abdakibart . for the treatment of hidradenitis suppurativa in the second quarter of. -- Cash, cash equivalents and short-term investments of approximately $98. million as of December 31, 2025 expected to provide runway into 2028. WAYNE, Pa., March 23, 2026  -- Avalo Therapeutics, Inc.  , a clinical stage biotechnology company fully dedicated to developing IL-1<BETA>-based treatments for immune-mediated inflammatory diseases, today announced business updates and year-end financial results for 2025.\"2025 was a year of disciplined execution focused on the LOTUS trial, and we are thrilled to be approaching a transformational milestone with our topline data release expected in the second quarter of 2026,\" said Dr. Garry Neil, Chief Executive Officer. \"We look forward to sharing the results which have the potential to demonstrate abdakibart's  high affinity inhibition of IL-1<BETA> and positive impact on addressing the large unmet need of ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","AVTX","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621583774","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2621583774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621583774?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:00","pubTimestamp":1774260000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTA","CMC","AGX","EPAC","FEMY","KALV","IMNN","AIR","BAK","ABOS","CELC","BYND","HUMA","CGNT","AUTL","MXCT","EVTL","CNTX","BCAX","BTGO","HYPD","EDAP","GOVX","DERM","ACHV","DEFT","IMDX","CCL","CTAS","CNM","KBH","CHWY","AVTX","FBRX","ABSI","CNXC","IKT","HSAI","DPRO","FENC","FUL","BRZE","ABVX","JBS","EQ","CNTB","DOO","BZAI","JEF","GUTS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalotx.com","stockEarnings":[{"period":"1week","weight":-0.0897},{"period":"1month","weight":-0.0524},{"period":"3month","weight":-0.1344},{"period":"6month","weight":-0.2679},{"period":"1year","weight":1.64},{"period":"ytd","weight":-0.2731}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.063135},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.010519},{"month":3,"riseRate":0.272727,"avgChangeRate":0.280205},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.090097},{"month":5,"riseRate":0.3,"avgChangeRate":-0.069789},{"month":6,"riseRate":0.7,"avgChangeRate":0.011587},{"month":7,"riseRate":0.5,"avgChangeRate":0.025049},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034606},{"month":9,"riseRate":0.6,"avgChangeRate":0.04604},{"month":10,"riseRate":0.6,"avgChangeRate":0.161359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.050828},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.047903}],"exchange":"NASDAQ","name":"Avalo Therapeutics Inc","nameEN":"Avalo Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Avalo Therapeutics Inc,AVTX,Avalo Therapeutics Inc股票,Avalo Therapeutics Inc股票老虎,Avalo Therapeutics Inc股票老虎国际,Avalo Therapeutics Inc行情,Avalo Therapeutics Inc股票行情,Avalo Therapeutics Inc股价,Avalo Therapeutics Inc股市,Avalo Therapeutics Inc股票价格,Avalo Therapeutics Inc股票交易,Avalo Therapeutics Inc股票购买,Avalo Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalo Therapeutics Inc(AVTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Avalo Therapeutics Inc(AVTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}